BP
REGN icon

Ballentine Partners’s Regeneron Pharmaceuticals REGN Stock Holding History

Ballentine Partners’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$657K Sell
1,054
-145
-12% -$98.7K 0.01% 476
2026
Q1 		$926K Buy
1,199
+90
+8% +$68.9K 0.01% 370
2025
Q4 		$856K Buy
1,109
+43
+4% +$29.2K 0.01% 363
2025
Q3 		$599K Buy
1,066
+105
+11% +$59.4K 0.01% 443
2025
Q2 		$505K Sell
961
-49
-5% -$27.3K 0.01% 480
2025
Q1 		$641K Buy
1,010
+93
+10% +$64K 0.01% 374
2024
Q4 		$653K Sell
917
-145
-14% -$122K 0.01% 368
2024
Q3 		$1.12M Buy
1,062
+50
+5% +$55.6K 0.02% 262
2024
Q2 		$1.06M Sell
1,012
-28
-3% -$27.1K 0.02% 246
2024
Q1 		$1M Buy
1,040
+285
+38% +$271K 0.02% 248
2023
Q4 		$663K Sell
755
-241
-24% -$198K 0.01% 304
2023
Q3 		$820K Buy
996
+283
+40% +$222K 0.02% 221
2023
Q2 		$512K Sell
713
-404
-36% -$311K 0.01% 311
2023
Q1 		$918K Buy
1,117
+342
+44% +$258K 0.02% 209
2022
Q4 		$559K Buy
775
+194
+33% +$143K 0.02% 257
2022
Q3 		$401K Buy
581
+233
+67% +$147K 0.01% 280
2022
Q2 		$206K Sell
348
-30
-8% -$19.5K 0.01% 398
2022
Q1 		$264K Buy
+378
New +$239K 0.01% 379
2016
Q3 		– Sell
-638
Closed -$222K – 228
2016
Q2 		$222K Buy
638
+13
+2% +$5.01K 0.02% 189
2016
Q1 		$225K Buy
+625
New +$258K 0.02% 183

Other funds holding REGN

Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
GA
GuoLine Advisory Singapore $1.07B AUM 26.27% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
WCM
Wedge Capital Management Charlotte, North Carolina $6.06B AUM 47.24% 1-Year Est. Return
AIP
ARS Investment Partners New York $2.29B AUM 113.95% 1-Year Est. Return
AP
Atwood & Palmer Kansas City, Missouri $1.87B AUM 24.22% 1-Year Est. Return
HCM
Howland Capital Management Boston, Massachusetts $2.77B AUM 19.56% 1-Year Est. Return
CNB
Czech National Bank Prague, Czech Republic $18.3B AUM 43.04% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return

Ballentine Partners's REGN Position: Q2 2026 in Review

Ballentine Partners reduced its Regeneron Pharmaceuticals (REGN) stake by 12% in Q2 2026, selling an estimated $98.7K and leaving 1,054 shares worth $657K. The position accounts for 0.01% of the portfolio, ranked #476.

Ballentine Partners first reported a position in REGN in Q1 2016 and has held it in 20 quarters since. The position peaked at $1.12M in Q3 2024. 208 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

  • Ballentine Partners held 1,054 shares of Regeneron Pharmaceuticals worth $657K as of Q2 2026.
  • Ballentine Partners sold 145 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $98.7K.
  • Regeneron Pharmaceuticals made up 0.01% of Ballentine Partners's portfolio in Q2 2026, its #476 holding.
  • Ballentine Partners first reported a position in Regeneron Pharmaceuticals in Q1 2016 and has held it in 20 quarters since.
  • Ballentine Partners's Regeneron Pharmaceuticals position peaked at $1.12M in Q3 2024.
  • 208 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Ballentine Partners's 13F filing for Q2 2026, filed 17 Jul 2026.